Patents Assigned to CSL Behring GmbH
  • Publication number: 20240000908
    Abstract: The invention relates to methods of treating antibody-mediated rejection in a subject comprising administering C1-INH to the subject according to a schedule with the following steps: (a) intravenously administering one or more iv-doses of C1-INH, (b) subcutaneously administering at least 10 sc-doses of C1-INH over several weeks, wherein each week at least one sc-dose is administered. The invention further relates to a method of treating antibody-mediated rejection in a transplant recipient comprising subcutaneously administering C1-INH over at least 10 weeks, wherein each week at least one sc-dose is administered.
    Type: Application
    Filed: November 18, 2021
    Publication date: January 4, 2024
    Applicant: CSL Behring GmbH
    Inventors: John Roberts, Marc Uknis, Christine Voigt
  • Patent number: 11744880
    Abstract: The invention pertains to a blood coagulation factor replacement product for use in the treatment or prophylaxis of bleedings of patients having an acquired coagulation factor deficiency or for use in the treatment or prophylaxis of bleedings of patients having a congenital deficiency of a coagulation factor. Said product comprises at least isolated prothrombin (Factor II) and isolated Antithrombin III (ATIII), whereby the molar ratio between ATIII to Factor II is at least 1:30. By administration of said product the patient's risk for a thromboembolic complication is reduced.
    Type: Grant
    Filed: February 9, 2018
    Date of Patent: September 5, 2023
    Assignee: CSL Behring GmbH
    Inventors: Eva Herzog, Gerald Hochleitner, Oliver Grottke
  • Publication number: 20220363715
    Abstract: The present invention relates to a process for purifying C1-esterase inhibitor (C1-Inh), and more in particular a Cl-Inh concentrate.
    Type: Application
    Filed: July 3, 2020
    Publication date: November 17, 2022
    Applicant: CSL Behring GmbH
    Inventors: Roopsee Anand, Sabrina Huneke-Vogt, Jennifer Krupka-Kloos, Martin Vey, Norbert Schulze
  • Patent number: 11345759
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: May 31, 2022
    Assignees: CSL Behring GmbH, CSL Ltd
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 10973891
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: April 13, 2021
    Assignees: CSL Behring GmbH, Universitaet Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Patent number: 10513560
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 27, 2017
    Date of Patent: December 24, 2019
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Publication number: 20190209948
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
    Type: Application
    Filed: December 10, 2018
    Publication date: July 11, 2019
    Applicant: CSL Behring GmbH
    Inventors: Hung Pham, Jeffrey Michael Hey, Darren Nguy
  • Patent number: 10286047
    Abstract: The present invention relates to a contact activation system inhibitor, preferably a C1INH, for use in the treatment and/or prevention of remote ischemia-reperfusion injury (IRI), comprising administering the contact activation system inhibitory to an individual.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 14, 2019
    Assignees: CSL Behring GmbH, Universität Bern
    Inventors: Rolf Spirig, Sylvia Miescher, Marc Nolte, Claudia Duehrkop-Sisewitsch, Robert Rieben
  • Patent number: 9987328
    Abstract: An inhibitor of FXII/FXIIa for the prevention of the formation and/or stabilization of thrombi during and/or after a medical procedure performed on a human or animal subject comprising contacting blood of said human or animal subject with artificial surfaces, wherein said inhibitor of FXII/FXIIa is administered before and/or during and/or after said medical procedure.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: June 5, 2018
    Assignee: CSL Behring GmbH
    Inventors: Stefan Zeitler, Marc Nolte, Stefan Schulte, Gerhard Dickneite, Ingo Pragst
  • Publication number: 20180119128
    Abstract: The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.
    Type: Application
    Filed: November 9, 2017
    Publication date: May 3, 2018
    Applicant: CSL Behring GmbH
    Inventors: Hubert METZNER, Thomas WEIMER, Stefan SCHULTE
  • Patent number: 9957329
    Abstract: This application relates to neurological inflammatory diseases, such as multiple sclerosis, and to methods of administering a Factor XII inhibitor to prevent, treat, or otherwise ameliorate the effects of a neurological inflammatory disease, such as multiple sclerosis. Agents and pharmaceutical compositions comprising agents which inhibit the activity of FXII are also provided.
    Type: Grant
    Filed: January 31, 2013
    Date of Patent: May 1, 2018
    Assignees: CSL Behring GmbH, CSL Ltd., Julius-Maximilians-Universitaet-Wuerzburg, Westfaelische Wilhelms-Universitaet Muenster
    Inventors: Sven Meuth, Kerstin Goebel, Christoph Kleinschnitz, Brent McKenzie, Marc Nolte
  • Patent number: 9856326
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 9856325
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: January 2, 2018
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Publication number: 20170274045
    Abstract: The invention relates to compositions comprising an isolated sugar for use in the treatment of von Willebrand disease and/or hemophilia A, wherein the sugar is an accessible sugar residue derived from ABO(H) blood group antigen.
    Type: Application
    Filed: June 14, 2017
    Publication date: September 28, 2017
    Applicant: CSL Behring GmbH
    Inventors: Stefan SCHULTE, Rolf SPIRIG, Sabine ZOLLNER, Michael MOSES, Wilfried WORMSBAECHER, Hans-Arnold STOEHR
  • Publication number: 20170143805
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
    Type: Application
    Filed: February 3, 2017
    Publication date: May 25, 2017
    Applicant: CSL Behring GmbH
    Inventors: Hung PHAM, Jeffrey Michael HEY, Darren NGUY
  • Publication number: 20170137536
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 18, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Publication number: 20170121423
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Application
    Filed: November 4, 2016
    Publication date: May 4, 2017
    Applicants: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte
  • Patent number: 9624307
    Abstract: Silent brain ischemia (SBI) or ischemia of other organs can result from an embolism that is introduced into the arterial system during a medical procedure. The application provides a method of administering a FXII inhibitor in a patient receiving a medical procedure and animal models useful for studying ischemia including SBI and ischemia in other organs, and for evaluating candidate therapeutics.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: April 18, 2017
    Assignees: The General Hospital Corporation, CSL Behring GmbH
    Inventors: Matthias Nahrendorf, Ralph Weissleder, Gerhard Dickneite, Guido Stoll, Marc Nolte
  • Patent number: 9598461
    Abstract: The present invention relates generally to a method of reducing the level of at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) in a solution comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and von Willebrand factor (VWF), the method comprising: (i) passing a feedstock comprising at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF through a hydrophobic charge-induction chromatographic resin under conditions selected such that at least one protein selected from the group consisting of plasminogen, tissue plasminogen activator and other protease(s) present in the feedstock is bound to the resin; and (ii) recovering a solution comprising the at least one protein selected from the group consisting of fibrinogen, Factor VIII and VWF which passes through the resin, wherein the concentration of the at least one protein selected from the group consisting of pl
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: March 21, 2017
    Assignee: CSL Behring GmbH
    Inventors: Hung Pham, Jeffrey Michael Hey, Darren Nguy
  • Patent number: 9518127
    Abstract: The invention relates to inhibitory anti-factor XII/FXIIa antibodies and methods of their use.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: December 13, 2016
    Assignees: CSL Behring GmbH, CSL Ltd.
    Inventors: Con Panousis, Veronika Rayzman, Andrew Nash, Michael Wilson, Stefan Schmidbauer, Marc Nolte